1. ISO 10993:17(2002) (R2012).Biological evaluation of medical devices – Part 17: Establishment of allowable limits for leachable substances.
2. Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics – Current challenges and approaches
3. Guidance for Industry.M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. US Department of Health and Human Services: Food and Drug Administration; Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). March 2018.
4. Considerations when deriving compound‐specific limits for extractables and leachables from pharmaceutical products: four case studies;Parris P.;Regul. Toxicol. Pharmacol.,2020
5. Guidance for Industry.Q3C Impurities: Residual Solvents. US Department of Health and Human Services: Food and Drug Administration; Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). December 1997.